--- title: "OVERCOME-TBI protocol: Long-term outcomes and microbiota–gut–brain axis after traumatic brain inju" id: "bmj-open-17-long-term-recovery-and-microbiota-gut-brain-axis-disruption-after-traumatic" canonical_url: "https://medichelpline.com/clinical-feed/bmj-open-17-long-term-recovery-and-microbiota-gut-brain-axis-disruption-after-traumatic" content_type: "clinical_feed_article" specialty: "Neurology" source_name: "BMJ Open" source_url: "http://bmjopen.bmj.com/cgi/content/short/16/9/e120552?rss=1" published_at: "2026-09-23T14:44:35.000Z" evidence_level: "Journal Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # OVERCOME-TBI protocol: Long-term outcomes and microbiota–gut–brain axis after traumatic brain inju ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-open-17-long-term-recovery-and-microbiota-gut-brain-axis-disruption-after-traumatic - **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md) - **Primary Source:** BMJ Open - **Source URL:** [Original Journal Publication](http://bmjopen.bmj.com/cgi/content/short/16/9/e120552?rss=1) - **Published At:** 2026-09-23T14:44:35.000Z - **Evidence Rating:** Journal Feed ## Executive GIST (TL;DR) - The OVERCOME-TBI study is a prospective observational protocol examining long-term recovery after **traumatic brain injury (TBI)** across all severities, integrating previously collected acute/subacute data with new chronic-phase assessments. - Two established cohorts are re-contacted: TBIcare (recruited 2011–2013) and PACoS-TBI (recruited 2020–2023). Chronic assessments occur at 2–5 and 12–15 years post-injury. - Up to 160 TBI patients and 30 orthopaedic injury controls will undergo multimodal evaluations including neurological and neuropsychological testing, advanced MRI, PET with the radioligand **[11C]PK11195**, blood proteomics, lipidomics and metabolomics, and faecal and intestinal microbiome profiling. - Colonoscopy biopsies will provide intestinal tissue samples; 10 patients with multiple sclerosis will serve as a positive control group for PET and blood biomarker sampling. - Primary outcomes are measures of **neuroinflammation** (biochemical assays and PET), longitudinal functional outcome measured by the **Glasgow Outcome Scale Extended**, and **gut microbiota composition**. - Statistical approaches include regression modelling and machine learning to identify predictors of poor recovery, progressive neurodegeneration markers and microbiome signatures associated with outcomes. - Ethical approval was granted by the Ethical Committee of the Wellbeing Services County of Southwest Finland; all participants provide written informed consent. - Results will be shared via peer-reviewed publications, conferences and stakeholder engagement, aiming to inform personalised diagnostics and potential therapeutic targets for chronic TBI consequences. - Trial registration: NCT06927063. ## Clinical Analysis & Structured Key Points Introduction Traumatic brain injury (TBI) is a major cause of long-term disability worldwide, but the pathophysiological mechanisms underlying its chronic sequelae remain incompletely understood. In addition to persistent neuroinflammation, evidence suggests that dysregulation of the gut microbiota influences brain recovery. The OVERCOME-TBI study investigates the long-term functional, cognitive, imaging, biochemical and gastrointestinal outcomes after TBI of all severities, with the aim of identifying biomarkers and microbiome signatures associated with progressive neurodegeneration and poor recovery. Methods and analysis This is a prospective, observational study with long-term follow-up of two previously established TBI cohorts - the Evidence-based Diagnostic and Treatment Planning Solution for Traumatic Brain Injuries (TBIcare; recruited 2011 - 2013) and the Pathophysiological Characterisation of Severe TBI (PACoS-TBI; recruited 2020 - 2023). The design combines prospectively collected acute and subacute data from the original cohorts with new cross-sectional assessments performed at chronic time points (2 - 5 and 12 - 15 years post-injury). Participants are re-contacted and re-consented for these chronic-phase assessments. Up to 160 patients with TBI and 30 orthopaedic injury controls will undergo multimodal examinations: neurological and neuropsychological testing, advanced MRI including multishell diffusion and resting-state functional MRI, positron emission tomography (PET) with the radioligand [ 11 C]PK11195, blood-based proteomics, lipidomics, metabolomics, faecal and intestinal microbiome profiling and colonoscopy biopsies. Moreover, 10 patients with multiple sclerosis (as a positive control group) will undergo PET imaging and sampling for blood biomarkers. Primary outcomes include neuroinflammatory burden (biochemical and PET), longitudinal functional outcomes (Glasgow Outcome Scale Extended) and gut microbiota composition. Statistical modelling, including regression models and machine learning, will be applied to identify predictors of outcome and disease progression. Ethics and dissemination Ethical approval has been obtained from the Ethical Committee of the Wellbeing Services County of Southwest Finland. Written informed consent will be obtained from all participants. The results will be disseminated through peer-reviewed publications, conference presentations and stakeholder engagement, with the aim of developing personalised diagnostics and novel therapeutic targets to alleviate the chronic consequences of TBI. Trial registration number NCT06927063 . ## Related Clinical Research - [Understanding the Complexity of Multiple Sclerosis Diagnosis: Lessons from Christina Applegate](https://medichelpline.com/clinical-feed/stat-news-0-opinion-christina-applegate-puts-a-face-on-one-of-the-most-consequential.md) - [Patient death reported in Bristol Myers Squibb CAR-T trial for multiple sclerosis](https://medichelpline.com/clinical-feed/stat-news-2-stat-patient-dies-in-bristol-myers-squibb-autoimmune-car-t-trial.md) - [Mitochondrial dysfunction in neurology: biomarkers for diagnosis, stratification and monitoring](https://medichelpline.com/clinical-feed/nature-reviews-neurology-0-mitochondrial-dysfunction-in-neurology-biomarkers-and-clinical-implications.md) - [Testing frequency explains most SDMT differences between natalizumab and rituximab in Swedish MS r](https://medichelpline.com/clinical-feed/medrxiv-22-more-tests-higher-scores-testing-frequency-and-sdmt-differences-between.md) - [Live Birth Rates in Swedish Women with Multiple Sclerosis, 2004–2022](https://medichelpline.com/clinical-feed/medrxiv-20-live-birth-rates-among-women-with-multiple-sclerosis-in-sweden-2004-to-2022-a.md) ## Navigation - [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.